Schopfer, Ulrich and Cottens, Sylvain (2015) Enabling New Targets by Integrated Lead Discovery. Drug Target Review, 2 (4). pp. 29-32. ISSN 2059-1349

Abstract

Advances in biomedical science and technology are directing attention to drug targets that were previously deemed difficult or even "un-druggable". At Novartis, we have re-designed our approach to lead discovery to exploit these opportunities. Placing biological understanding of disease at the center of lead discovery strategies, we make extensive use of focussed screening in complex biologically relevant models. We emphasize methods that build confidence also in hits with weak activity and build on synergies between different technologies to answer key scientific questions in projects. Here we describe the scientific, cultural and organizational changes that had to be implemented to introduce this concept of "Integrated Lead Discovery".

Item Type:	Article
Date Deposited:	29 Jul 2016 00:45
Last Modified:	29 Jul 2016 00:45
URI:	https://oak.novartis.com/id/eprint/26150